Table 1.
Patient demographics, clinical characteristics, and biopsy results for patients who underwent mpMRI followed by mpMRI-TRUS fusion-guided biopsy and systematic 12-core biopsy, separated into three cohorts
| Cohort 1 | Cohort 2 | Cohort 3 | Total | P-value | |
|---|---|---|---|---|---|
| Patients, n (%) | 230 (15.1) | 537 (35.1) | 761 (49.8) | 1528 | |
| Age, years, median (IQR) | 61.0 (11.3) | 62.0 (9.0) | 64.0 (11.0) | 63.0 (10.0) | < 0.001 |
| Race, n (%) | 0.33 | ||||
| White | 167 (72.6) | 430 (80.0) | 590 (77.5) | 1187 (79.1) | |
| Black | 34 (14.8) | 88 (16.4) | 116 (15.2) | 238 (15.9) | |
| Other | 29 (12.6) | 19 (3.5) | 55 (7.2) | 103 (6.7) | |
| PSA, ng ml−1, median (IQR) | 6.1 (5.7) | 6.9 (6.57) | 6.5 (5.6) | 6.5 (5.8) | 0.03 |
| Clinical Stage, n (%) | 0.57 | ||||
| cTIc | 46 (86.8) | 489 (91.2) | 685 (90.2) | 1220 (90.8) | |
| >T2a | 7 (13.2) | 47 (8.8) | 70 (9.3) | 124 (9.3) | |
| Fbx targets, median (IQR) | 6 (4) | 5 (2) | 4 (4) | 4(4) | < 0.001 |
| Highest MRI suspicion score, n (%) | |||||
| Low to moderate | 188 (81.7) | 434 (80.8) | 582 (76.5) | 1204 (78.8) | |
| Moderate-high to high | 42 (18.3) | 103 (19.2) | 179 (23.5) | 324 (21.2) | 0.122 |
| Systematic 12-core biopsy | |||||
| Gleason score, n (%) | 0.009 | ||||
| Benign | 126 (54.8) | 288 (53.6) | 382 (71.1) | 796 (52.1) | |
| 6 | 53 (23.0) | 115 (21.4) | 149 (19.7) | 317 (20.8) | |
| 7 | 32 (13.9) | 76 (14.2) | 161 (21.2) | 269 (17.6) | |
| >8 | 19 (8.3) | 58 (10.8) | 69 (9.1) | 144 (9.4) | |
| mpMRI-TRUS fusion-guided biopsy | |||||
| Gleason score, n (%) | < 0.001 | ||||
| Benign | 128 (55.7) | 290 (54.0) | 388 (51.0) | 806 (52.8) | |
| 6 | 45 (19.5) | 78 (14.5) | 96 (12.6) | 219 (14.3) | |
| 7 | 34 (14.8) | 83 (15.5) | 181 (23.8) | 298 (19.4) | |
| >8 | 23 (10) | 86 (16.0) | 96 (12.6) | 205 (13.4) | |
| CS PCa, n (%) | 69 (30.1) | 197 (36.8) | 332 (43.7) | 600 (39.3) | < 0.001 |
Abbreviations: IQR, interquartile range; MRI, magnetic resonance imaging; mpMRI, multiparametric MRI; PCa, prostate cancer.